A Phase 2 interventional study of Relatlimab and Nivolumab in Melanoma, sponsored by John Kirkwood. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by John Kirkwood · Phase 2, Interventional, and Treatment
How we know · 5 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing relatlimab in Melanoma — 6 open to participants now, 10 under way, 1 of them phase 3. relatlimab · Melanoma.
Among the 16 studies testing relatlimab in Melanoma, this one is the 9th largest by enrollment, is one of 2 that started in 2019, is one of 10 in phase 2, and was the 3rd registered.
3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.
Browse Melanoma studies →6 of the 16 studies testing relatlimab in Melanoma are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
relatlimab: first FDA approval 2022 (OPDUALAG), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 2 · Phase 4 1
First in 2015; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is close to the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 48 across the 16 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 16 have an industry lead sponsor. The 9 most frequent:
John Kirkwood is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
John Kirkwood has 8 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
1 of the studies testing relatlimab in Melanoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712927Stanford UniversityTrial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing relatlimab in Melanoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main goal of this study is to evaluate the antitumor activity of relatlimab and nivolumab in combination in subjects with unresectable or metastatic melanoma who have not received prior treatment with immunotherapy.
This study will evaluate the antitumor activity of anti-LAG3 monoclonal antibody relatlimab and the anti-PD1 monoclonal antibody nivolumab in combination in subjects with unresectable or metastatic melanoma who have not received prior treatment with immunotherapy. The trial is designed with a lead-in phase of 2 cycles (4 week) treatment of either nivolumab, relatlimab, or the combination of nivolumab/relatlimab, followed by a combination phase of nivolumab/relatlimab treatment in all subjects. This lead-in design with accompanying tumor biopsies and peripheral blood analyses will enable mechanistic analyses of the effect of LAG3 and PD1 blockade alone and in combination to enhance understanding of mechanisms of response and resistance. Duration of response, progression free survival, and safety will be assessed as secondary objectives.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Known or suspected , with the following exceptions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cycle 1: Relatlimab (BMS-986016) is supplied as a sterile 10mg/mL formulation to be administered as an intravenous (IV) infusion at 160 mg IV for the first 4 weeks (cycle 1). Cycle 2+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV once every 4 weeks.
Drug: Relatlimab
Cycle 1: Nivolumab (BMS-936558) is supplied as a sterile 10-mg/mL formulation to be administered as an IV infusion at 480 mg IV for the first 4 weeks. Cycle 2+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV once every 4 weeks.
Drug: Nivolumab
Cycle 1+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV for the first 4 weeks (Cycle 1), then once every 4 weeks afterwards.
Drug: Relatlimab + Nivolumab
Relatlimab (BMS-986016) - 10mg/mL formulation to be administered as an intravenous (IV) infusion at 160 mg IV.
Also known as: BMS-986016
Nivolumab (BMS-936558) - 10-mg/mL formulation to be administered as an IV infusion at 480 mg IV.
Also known as: BMS-936558
Drug pages: RelatlimabStudies of RelatlimabRelatlimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Combination (Relatlimab + Nivolumab) therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV.
Also known as: BMS-986016 and BMS-936558
LAG3 Gene Expression From scRNAseq
Percent Lymphocyte-activation gene 3 (LAG3) level (cell surface molecule expressed on activated T cells) expression from scRNAseq
Time frame: At Baseline
LAG3 Gene Expression From scRNAseq
Percent Lymphocyte-activation gene 3 (LAG3) level (cell surface molecule expressed on activated T cells) expression from scRNAseq
Time frame: At Week 4
PD1 Expression
Percent PD1 (programmed cell death protein 1) expression after completion of lead-in phase.
Time frame: At baseline (Week 0)
PD1 Expression
Percent PD1 (programmed cell death protein 1) expression after completion of lead-in phase.
Time frame: At Week 4
Change in Tumor Size
Percentage change in tumor size assessed per Response Evaluation Criteria in Solid Tumors. Per RECIST 1.1, Tumor lesions: Must be accurately measured in at least one dimension (longest diameter in the plane of measurement is to be recorded) with a minimum size of: * 10 mm by CT scan (CT scan slice thickness no greater than 5 mm; see Appendix II on imaging guidance). * 10 mm caliper measurement by clinical exam (lesions which cannot be accurately measured with calipers should be recorded as non-measurable). * 20 mm by chest X-ray.
Time frame: At baseline and at 4 weeks
Overall Response Rate (ORR)
Percent of participants experiencing Complete Response (CR) + Number of participants experiencing Partial Response (PR)/total patients assessed. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: Beginning at 12 weeks post initial treatment, up to 4 years
Overall Response Rate (ORR) - ITT (Intent-to-treat) Population
Percent of participants experiencing Complete Response (CR) + Number of participants experiencing Partial Response (PR)/total patients assessed. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: Beginning at 12 weeks post initial treatment, up to 4 years
Secondary Outcome: Clinical Benefit Rate
Percent of patients with Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) / total patients assessed per RECIST v1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: 12 weeks post initial treatment, up to 4 years
Clinical Benefit Rate - ITT (Intent-to-treat) Population
Percent of patients with Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) / total patients assessed per RECIST v1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: 12 weeks post initial treatment, up to 4 years
Duration of Response
Time from first documented Complete Response (CR) or Partial Response (PR) until the first date that progressive disease is objectively documented. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: 12 weeks post initial treatment, up to 4 years
Progression-free Survival (PFS)
Progression-free survival is defined as the time between the date of randomization and the first date of documented progression or death due to any cause, whichever occurs first. Per RECIST v1.1, Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Up to 4 years
Progression-free Survival (PFS) by Lead-in Arm
Progression-free survival is defined as the time between the date of randomization and the first date of documented progression or death due to any cause, whichever occurs first. Per RECIST v1.1, Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Up to 4 years
Overall Survival (OS)
Overall survival is defined as the time between the date of randomization and the date of death due to any cause.
Time frame: Up to 4 years
CD8+ Tumor Infiltrating Lymphocytes
Number of CD8+ tumor infiltrating lymphocytes present.
Time frame: At Baseline
CD8+ Tumor Infiltrating Lymphocytes
Number of CD8+ tumor infiltrating lymphocytes present.
Time frame: At Week 4
CD4+ Tumor Infiltrating Lymphocytes
Number of CD4+ tumor infiltrating lymphocytes present.
Time frame: At Week 4
CD4+ Tumor Infiltrating Lymphocytes
Number of CD4+ tumor infiltrating lymphocytes present.
Time frame: At Baseline
LAG3 Levels - PBMC
To determine the amount of LAG3 expressed on activated T cells in the blood through single-cell RNA sequencing. The LAG3 expression is reported as the natural log (ln) of the number of LAG3 transcripts divided by the number of total mapped reads plus 1.
Time frame: At Baseline
LAG3 Levels - PBMC
To determine the amount of LAG3 expressed on activated T cells in the blood through single-cell RNA sequencing. The LAG3 expression is reported as the natural log (ln) of the number of LAG3 transcripts divided by the number of total mapped reads plus 1.
Time frame: At Week 4
LAG3 Levels - TIL
To determine the amount of LAG3 expressed on activated tumor infiltrating lymphocytes (TIL) through single-cell RNA sequencing. The LAG3 expression is reported as the natural log (ln) of the number of LAG3 transcripts divided by the number of total mapped reads plus 1.
Time frame: At Baseline
LAG3 Levels - PBMC
To determine the amount of LAG3 expressed on activated T cells in the blood through single-cell RNA sequencing. The LAG3 expression is reported as the natural log (ln) of the number of LAG3 transcripts divided by the number of total mapped reads plus 1.
Time frame: At Week 16
LAG3 Levels - TIL
To determine the amount of LAG3 expressed on activated tumor infiltrating lymphocytes (TIL) through single-cell RNA sequencing. The LAG3 expression is reported as the natural log (ln) of the number of LAG3 transcripts divided by the number of total mapped reads plus 1.
Time frame: At Week 4
PD-1 Expression in PBMC
To determine the amount of PD-1 (programmed cell death protein 1) expressed on PBMCs through single-cell RNA sequencing in treated patients. The PD-1 expression is reported as the natural log (ln) of the number of PD-1 transcripts divided by the number of total mapped reads plus 1.
Time frame: At Baseline
PD-1 Expression in PBMC
To determine the amount of PD-1 (programmed cell death protein 1) expressed on PBMCs through single-cell RNA sequencing in treated patients. The PD-1 expression is reported as the natural log (ln) of the number of PD-1 transcripts divided by the number of total mapped reads plus 1.
Time frame: At Week 4
PD-1 Expression in PBMC
To determine the amount of PD-1 (programmed cell death protein 1) expressed on PBMCs through single-cell RNA sequencing in treated patients. The PD-1 expression is reported as the natural log (ln) of the number of PD-1 transcripts divided by the number of total mapped reads plus 1.
Time frame: At Week 16
PD-1 Expression in TIL
To determine the amount of PD-1 (programmed cell death protein 1) expressed on TILs through single-cell RNA sequencing in treated patients. The PD-1 expression is reported as the natural log (ln) of the number of PD-1 transcripts divided by the number of total mapped reads plus 1.
Time frame: At Baseline
PD-1 Expression in TIL
To determine the amount of PD-1 (programmed cell death protein 1) expressed on TILs through single-cell RNA sequencing in treated patients. The PD-1 expression is reported as the natural log (ln) of the number of PD-1 transcripts divided by the number of total mapped reads plus 1.
Time frame: At Week 4
Cell Effector/Memory Status - TIL
Measure of cells that have previously encountered and responded to their cognate antigen in TIL.
Time frame: At Baseline
Cell Effector/Memory Status - TIL
Measure of cells that have previously encountered and responded to their cognate antigen in TIL.
Time frame: At Week 4
Cell Effector/Memory Status - PBMCs
Measure of cells that have previously encountered and responded to their cognate antigen in PBMCs.
Time frame: At Baseline
Cell Effector/Memory Status - PBMC
Measure of cells that have previously encountered and responded to their cognate antigen in PBMCs.
Time frame: At Week 4
Cell Effector/Memory Status - PBMC
Measure of cells that have previously encountered and responded to their cognate antigen in PBMCs.
Time frame: At Week 16
Regulatory T Cell (Treg) Marker Levels - PMBCs
Amount of Regulatory T cell (Treg) markers present in PBMCs in treated patients.
Time frame: At Baseline
Regulatory T Cell (Treg) Marker Levels - PMBCs
Amount of Regulatory T cell (Treg) markers present in PBMCs in treated patients.
Time frame: At Week 4
Regulatory T Cell (Treg) Marker Levels - PMBCs
Amount of Regulatory T cell (Treg) markers present in PBMCs in treated patients.
Time frame: At Week 16
Regulatory T Cell (Treg) Marker Levels - TIL
Amount of Regulatory T cell (Treg) markers present in TILs in treated patients.
Time frame: At Baseline
Regulatory T Cell (Treg) Marker Levels - TIL
Amount of Regulatory T cell (Treg) markers present in TILs in treated patients.
Time frame: At Week 4
Activation and Maturation of Dendritic Cells - PBMC
Measure of expression of activation and maturation of dendritic cells in PBMCs.
Time frame: At Baseline
Activation and Maturation of Dendritic Cells - PBMC
Measure of expression of activation and maturation of dendritic cells in PBMCs.
Time frame: At Week 4
Activation and Maturation of Dendritic Cells - PBMC
Measure of expression of activation and maturation of dendritic cells in PBMCs.
Time frame: At Week 16
Activation and Maturation of Dendritic Cells - TIL
Measure of expression of activation and maturation of dendritic cells in tumor (TIL).
Time frame: At Baseline
Activation and Maturation of Dendritic Cells - TIL
Measure of expression of activation and maturation of dendritic cells in tumor (TIL).
Time frame: At Week 4
Soluble LAG3 Levels - PBMC
Amount of LAG3 (cell surface molecule expressed on activated T cells) protein present in blood in patients that had previously demonstrated complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: At the time of disease progression - up to 4 years
Soluble LAG3 Levels - TIL
Amount of LAG3 (cell surface molecule expressed on activated T cells) protein present in tumor tissue in patients that had previously demonstrated complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: At the time of disease progression - up to 4 years
Granzyme B Serum Levels
Level of granzyme B (a serine protease secreted cells to mediate apoptosis in target cells) in serum.
Time frame: At 2 weeks prior first study treatment, at 4 weeks, at 12 weeks
T Cell Count
Number of T cells present in TIL or PBMC.
Time frame: At 4 weeks
T Cell Count
Number of T cells present in TIL or PBMC.
Time frame: At 12 weeks
T Cell Count
Number of T cells present in TIL or PBMC.
Time frame: At the time of disease progression - up to 4 years
Single Cell RNA Sequencing
The presence and quantity of RNA in in blood and tumor tissue.
Time frame: 2 weeks
Single Cell RNA Sequencing
The presence and quantity of RNA in in blood and tumor tissue.
Time frame: At 4 weeks post Cycle 1
Single Cell RNA Sequencing
The presence and quantity of RNA in in blood and tumor tissue.
Time frame: At week 16 (12 weeks post combination treatment (3 cycles)
Single Cell RNA Sequencing
The presence and quantity of RNA in in blood and tumor tissue in patients that had previously demonstrated complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: At the time of disease progression - up to 4 years
| Milestone | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Started | 14 | 15 | 14 |
| Completed | 14 | 15 | 14 |
| Not completed | 0 | 0 | 0 |
Percent Lymphocyte-activation gene 3 (LAG3) level (cell surface molecule expressed on activated T cells) expression from scRNAseq
| percent | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| LAG3 Gene Expression From scRNAseq | 0.78 ± 1.27 | 2.94 ± 4.28 | 9.37 ± 10.93 |
Percent Lymphocyte-activation gene 3 (LAG3) level (cell surface molecule expressed on activated T cells) expression from scRNAseq
| percent | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| LAG3 Gene Expression From scRNAseq | 0.96 ± 2.01 | 13.12 ± 22.02 | 13.50 ± 9.31 |
Percent PD1 (programmed cell death protein 1) expression after completion of lead-in phase.
| percent | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| PD1 Expression | 9.29 ± 14.77 | 5.43 ± 5.09 | 12.28 ± 9.47 |
Percent PD1 (programmed cell death protein 1) expression after completion of lead-in phase.
| percent | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| PD1 Expression | 2.91 ± 3.11 | 5.78 ± 4.78 | 6.19 ± 5.09 |
Percentage change in tumor size assessed per Response Evaluation Criteria in Solid Tumors. Per RECIST 1.1, Tumor lesions: Must be accurately measured in at least one dimension (longest diameter in the plane of measurement is to be recorded) with a minimum size of: * 10 mm by CT scan (CT scan slice thickness no greater than 5 mm; see Appendix II on imaging guidance). * 10 mm caliper measurement by clinical exam (lesions which cannot be accurately measured with calipers should be recorded as non-measurable). * 20 mm by chest X-ray.
| percent change | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Change in Tumor Size | 10 (-2 to 28) | 3 (-8 to 18) | -5 (-6 to 1) |
Percent of participants experiencing Complete Response (CR) + Number of participants experiencing Partial Response (PR)/total patients assessed. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| percentage of patients | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Overall Response Rate (ORR) | 20 (3.68 to 50.69) | 50 (26.36 to 73.64) | 46.15 (22.4 to 71.3) |
Percent of participants experiencing Complete Response (CR) + Number of participants experiencing Partial Response (PR)/total patients assessed. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| percentage of patients | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Overall Response Rate (ORR) - ITT (Intent-to-treat) Population | 14.29 (2.6 to 38.54) | 46.67 (24.37 to 70) | 42.86 (20.61 to 67.5) |
Percent of patients with Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) / total patients assessed per RECIST v1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| Percentage | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Secondary Outcome: Clinical Benefit Rate | 80 (49.31 to 96.32) | 78.57 (53.43 to 93.89) | 76.92 (50.54 to 93.4) |
Percent of patients with Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) / total patients assessed per RECIST v1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| Percentage | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Clinical Benefit Rate - ITT (Intent-to-treat) Population | 57.14 (32.5 to 79.39) | 73.33 (48.92 to 90.33) | 71.43 (46 to 89.6) |
Time from first documented Complete Response (CR) or Partial Response (PR) until the first date that progressive disease is objectively documented. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| months | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Duration of Response | NA (22.4 to NA) | NA (37.5 to NA) | NA (NA to NA) |
Progression-free survival is defined as the time between the date of randomization and the first date of documented progression or death due to any cause, whichever occurs first. Per RECIST v1.1, Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| months | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Progression-free Survival (PFS) | 1.9 (0.9 to NA) | 4.7 (1.0 to NA) | 14.7 (9.1 to NA) |
Progression-free survival is defined as the time between the date of randomization and the first date of documented progression or death due to any cause, whichever occurs first. Per RECIST v1.1, Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| months | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Progression-free Survival (PFS) by Lead-in Arm | 1.9 (0.9 to NA) | 4.7 (1.0 to NA) | 14.7 (9.1 to NA) |
Overall survival is defined as the time between the date of randomization and the date of death due to any cause.
| months | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Overall Survival (OS) | 23.6 (12.1 to NA) | 41.1 (19.0 to NA) | NA (27.7 to NA) |
Number of CD8+ tumor infiltrating lymphocytes present.
| proportion of immune cells | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| CD8+ Tumor Infiltrating Lymphocytes | 0.410590278 (0.143863179 to 0.513750731) | 0.359393872 (0.2011635366359 to 0.549686402) | 0.36241623 (0.200645966 to 0.4794291948955) |
Number of CD8+ tumor infiltrating lymphocytes present.
| proportion of immune cells | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| CD8+ Tumor Infiltrating Lymphocytes | 0.496584699 (0.451612903 to 0.5733944954128) | 0.382900483 (0.271371353 to 0.47105706) | 0.519125683 (0.4189190000300 to 0.6266313145408) |
Number of CD4+ tumor infiltrating lymphocytes present.
| proportion of immune cells | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| CD4+ Tumor Infiltrating Lymphocytes | 0.23392283 (0.150561798 to 0.281420765) | 0.194253553 (0.058145753 to 0.2949838417982) | 0.220195639 (0.175148548 to 0.257110926) |
Number of CD4+ tumor infiltrating lymphocytes present.
| proportion of immune cells | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| CD4+ Tumor Infiltrating Lymphocytes | 0.221945137 (0.136363636 to 0.32193159) | 0.236556234 (0.2097374566643 to 0.277051228) | 0.24424409 (0.213976252 to 0.392482686) |
To determine the amount of LAG3 expressed on activated T cells in the blood through single-cell RNA sequencing. The LAG3 expression is reported as the natural log (ln) of the number of LAG3 transcripts divided by the number of total mapped reads plus 1.
| ln(LAG3 transcripts/totalmappedreads+1) | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| LAG3 Levels - PBMC | 117.4181801 (61.54439729 to 294.4849249) | 87.41155574 (47.96758893 to 142.8924017) | 81.63475936 (70.23308523 to 142.5931631) |
To determine the amount of LAG3 expressed on activated T cells in the blood through single-cell RNA sequencing. The LAG3 expression is reported as the natural log (ln) of the number of LAG3 transcripts divided by the number of total mapped reads plus 1.
| ln(LAG3 transcripts/totalmappedreads+1) | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| LAG3 Levels - PBMC | 24.413734087489 (9.3474180371759 to 62.236318580783) | 85.234642328843 (18.302744806527 to 153.60255356972) | 114.21499509798 (38.868567296591 to 207.59732584449) |
To determine the amount of LAG3 expressed on activated tumor infiltrating lymphocytes (TIL) through single-cell RNA sequencing. The LAG3 expression is reported as the natural log (ln) of the number of LAG3 transcripts divided by the number of total mapped reads plus 1.
| ln(LAG3 transcripts/totalmappedreads+1) | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| LAG3 Levels - TIL | 553.0461253 (41.26380993 to 1527.474199) | 781.0925834 (227.8971686 to 2620.194512) | 294.6551121 (48.9453378 to 671.3791451) |
To determine the amount of LAG3 expressed on activated T cells in the blood through single-cell RNA sequencing. The LAG3 expression is reported as the natural log (ln) of the number of LAG3 transcripts divided by the number of total mapped reads plus 1.
| ln(LAG3 transcripts/totalmappedreads+1) | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| LAG3 Levels - PBMC | 78.30750135 (39.7607976 to 105.623955) | 208.2743213 (92.76860627 to 403.4555187) | 115.7683188 (82.53645799 to 186.7920792) |
To determine the amount of LAG3 expressed on activated tumor infiltrating lymphocytes (TIL) through single-cell RNA sequencing. The LAG3 expression is reported as the natural log (ln) of the number of LAG3 transcripts divided by the number of total mapped reads plus 1.
| ln(LAG3 transcripts/totalmappedreads+1) | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| LAG3 Levels - TIL | 484.95998714484 (349.03637689208 to 673.13564639344) | 181.73348534061 (108.66150695992 to 280.97789375502) | 191.56231622054 (101.93016786268 to 1468.6099534725) |
To determine the amount of PD-1 (programmed cell death protein 1) expressed on PBMCs through single-cell RNA sequencing in treated patients. The PD-1 expression is reported as the natural log (ln) of the number of PD-1 transcripts divided by the number of total mapped reads plus 1.
| ln(PD-1 transcripts/totalmappedreads+1) | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| PD-1 Expression in PBMC | 35.71568809 (16.03550284 to 57.00538064) | 21.75600549 (15.15743416 to 35.4023936) | 25.26034324 (18.6050362 to 42.22906242) |
To determine the amount of PD-1 (programmed cell death protein 1) expressed on PBMCs through single-cell RNA sequencing in treated patients. The PD-1 expression is reported as the natural log (ln) of the number of PD-1 transcripts divided by the number of total mapped reads plus 1.
| ln(PD-1 transcripts/totalmappedreads+1) | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| PD-1 Expression in PBMC | 4.395254969 (1.524867838 to 27.44315979) | 32.91097578 (15.04585236 to 60.3081099) | 37.82897218 (11.0244881 to 69.37037671) |
To determine the amount of PD-1 (programmed cell death protein 1) expressed on PBMCs through single-cell RNA sequencing in treated patients. The PD-1 expression is reported as the natural log (ln) of the number of PD-1 transcripts divided by the number of total mapped reads plus 1.
| ln(PD-1 transcripts/totalmappedreads+1) | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| PD-1 Expression in PBMC | 28.53794861 (13.86309395 to 51.9408153) | 88.7381496 (39.56943112 to 178.7760098) | 59.92440919 (38.9608126 to 96.098883) |
To determine the amount of PD-1 (programmed cell death protein 1) expressed on TILs through single-cell RNA sequencing in treated patients. The PD-1 expression is reported as the natural log (ln) of the number of PD-1 transcripts divided by the number of total mapped reads plus 1.
| ln(PD-1 transcripts/totalmappedreads+1) | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| PD-1 Expression in TIL | 230.9153184 (27.24279784 to 489.0740512) | 449.2734698 (168.6028866 to 885.1304368) | 239.7028054 (28.36920071 to 407.0256233) |
To determine the amount of PD-1 (programmed cell death protein 1) expressed on TILs through single-cell RNA sequencing in treated patients. The PD-1 expression is reported as the natural log (ln) of the number of PD-1 transcripts divided by the number of total mapped reads plus 1.
| ln(PD-1 transcripts/totalmappedreads+1) | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| PD-1 Expression in TIL | 228.75905461118 (29.378008590205 to 314.54965409338) | 52.286295752816 (25.095455416135 to 118.50159633512) | 97.373785446401 (54.125072015474 to 723.67240171323) |
Measure of cells that have previously encountered and responded to their cognate antigen in TIL.
| proportion of immune cells | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| memory | 0.032769556 (0.022393822 to 0.055555556) | 0.04014046 (0.026397003 to 0.079803468) | 0.072042923 (0.020349099 to 0.219567669) |
| effector | 0.005644028 (0.003943448 to 0.069638695) | 0.004836982 (0.003384551 to 0.011538082) | 0.00315595 (0.002346804 to 0.00571541) |
Measure of cells that have previously encountered and responded to their cognate antigen in TIL.
| proportion of immune cells | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| memory | 0.024393456 (0.018188142 to 0.036117078) | 0.050310559 (0.024560063 to 0.069113471) | 0.027002762 (0.017210365 to 0.041072618) |
| effector | 0.003741315 (0.002638522 to 0.008) | 0.007784912 (0.003288969 to 0.00921277) | 0.006480295 (0.002192184 to 0.015131579) |
Measure of cells that have previously encountered and responded to their cognate antigen in PBMCs.
| proportion of immune cells | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| memory | 0.173913043 (0.076345432 to 0.245737212) | 0.137828185 (0.113406637 to 0.181557067) | 0.198312236 (0.121602932 to 0.305413895) |
| effector | 0.029087262 (0.007633588 to 0.078760491) | 0.023693761 (0.018095238 to 0.033324224) | 0.01420765 (0.013335198 to 0.040356548) |
Measure of cells that have previously encountered and responded to their cognate antigen in PBMCs.
| proportion of immune cells | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| memory | 0.199023648 (0.141758242 to 0.273277512) | 0.162300324 (0.078517448 to 0.243674507) | 0.171945701 (0.089264386 to 0.347987251) |
| effector | 0.025974026 (0.019073923 to 0.046315789) | 0.011019284 (0.009361856 to 0.023844932) | 0.029145316 (0.014079027 to 0.038629997) |
Measure of cells that have previously encountered and responded to their cognate antigen in PBMCs.
| proportion of immune cells | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| memory | 0.26744186 (0.224274406 to 0.464285714) | 0.181510619 (0.0847756 to 0.375080749) | 0.184960054 (0.11202629 to 0.250726645) |
| effector | 0.026155752 (0.018633783 to 0.040069648) | 0.010531062 (0.006688079 to 0.01555367) | 0.010721374 (0.007409468 to 0.020016729) |
Amount of Regulatory T cell (Treg) markers present in PBMCs in treated patients.
| proportion of immune cells | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Regulatory T Cell (Treg) Marker Levels - PMBCs | 0.031311275 (0.027668814 to 0.039353362) | 0.032663631 (0.025531943 to 0.038065535) | 0.025919732 (0.013928831 to 0.041448479) |
Amount of Regulatory T cell (Treg) markers present in PBMCs in treated patients.
| proportion of immune cells | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Regulatory T Cell (Treg) Marker Levels - PMBCs | 0.027264981 (0.017635861 to 0.051930576) | 0.047009262 (0.036717905 to 0.052503788) | 0.046875 (0.027912065 to 0.053002957) |
Amount of Regulatory T cell (Treg) markers present in PBMCs in treated patients.
| proportion of immune cells | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Regulatory T Cell (Treg) Marker Levels - PMBCs | 0.056900222 (0.028511821 to 0.075614489) | 0.044996348 (0.036690206 to 0.049494691) | 0.038493371 (0.03643035 to 0.045096718) |
Amount of Regulatory T cell (Treg) markers present in TILs in treated patients.
| proportion of immune cells | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Regulatory T Cell (Treg) Marker Levels - TIL | 0.05866008 (0.036024306 to 0.093516209) | 0.058558335 (0.047202783 to 0.079397021) | 0.067705317 (0.047454931 to 0.098647656) |
Amount of Regulatory T cell (Treg) markers present in TILs in treated patients.
| proportion of immune cells | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Regulatory T Cell (Treg) Marker Levels - TIL | 0.056949153 (0.042696629 to 0.074121289) | 0.026785714 (0.016600266 to 0.063822859) | 0.065735998 (0.049323821 to 0.097586207) |
Measure of expression of activation and maturation of dendritic cells in PBMCs.
| proportion of immune cells | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Activation and Maturation of Dendritic Cells - PBMC | 0.03070015 (0.021834008 to 0.041250195) | 0.036025924 (0.021281652 to 0.048815284) | 0.030824639 (0.014091698 to 0.0473892638630) |
Measure of expression of activation and maturation of dendritic cells in PBMCs.
| proportion of immune cells | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Activation and Maturation of Dendritic Cells - PBMC | 0.03922571 (0.03139739 to 0.058189597) | 0.048762416 (0.039213563 to 0.087995338) | 0.035719581 (0.012278647 to 0.038502674) |
Measure of expression of activation and maturation of dendritic cells in PBMCs.
| proportion of immune cells | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Activation and Maturation of Dendritic Cells - PBMC | 0.032520325 (0.026083467 to 0.042553191) | 0.037229413 (0.025329726 to 0.052559771) | 0.022962689 (0.012496152 to 0.035273683) |
Measure of expression of activation and maturation of dendritic cells in tumor (TIL).
| proportion of immune cells | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Activation and Maturation of Dendritic Cells - TIL | 0.036315018 (0.029843818 to 0.072159091) | 0.053093156 (0.04276735 to 0.080816642) | 0.038510911 (0.018592677 to 0.0664646027278) |
Measure of expression of activation and maturation of dendritic cells in tumor (TIL).
| proportion of immune cells | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Activation and Maturation of Dendritic Cells - TIL | 0.088495575 (0.076190476 to 0.090909091) | 0.032432432 (0.012600229 to 0.081081081) | 0.047619048 (0.023310023 to 0.0625) |
Amount of LAG3 (cell surface molecule expressed on activated T cells) protein present in blood in patients that had previously demonstrated complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
No measurements were reported for this outcome.
Amount of LAG3 (cell surface molecule expressed on activated T cells) protein present in tumor tissue in patients that had previously demonstrated complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
No measurements were reported for this outcome.
Level of granzyme B (a serine protease secreted cells to mediate apoptosis in target cells) in serum.
No measurements were reported for this outcome.
Number of T cells present in TIL or PBMC.
No measurements were reported for this outcome.
Number of T cells present in TIL or PBMC.
No measurements were reported for this outcome.
The presence and quantity of RNA in in blood and tumor tissue.
Results for this outcome have not been posted.
The presence and quantity of RNA in in blood and tumor tissue.
Results for this outcome have not been posted.
The presence and quantity of RNA in in blood and tumor tissue.
Results for this outcome have not been posted.
The presence and quantity of RNA in in blood and tumor tissue in patients that had previously demonstrated complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Results for this outcome have not been posted.
Number of T cells present in TIL or PBMC.
No measurements were reported for this outcome.
Collected over Adverse Events Data, collected for 5 years, 4 months: Relatlimab Arm: combined data for all treatment cycles Nivolumab Arm: combined data for all treatment cycles Relatlimab + Nivolumab Arm: combined data for all treatment cycles All-Cause Mortality - data collected for up to 6 years from patient randomization.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Relatlimab | 8/14 (57.1%) | 6/14 (42.9%) | 14/14 (100%) |
| Nivolumab | 7/15 (46.7%) | 9/15 (60%) | 15/15 (100%) |
| Relatlimab + Nivolumab | 5/14 (35.7%) | 7/14 (50%) | 14/14 (100%) |
| Event | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| Death NOSGENERAL DISORDERS | 2/14 | 0/15 | 0/14 |
| FatigueGENERAL DISORDERS | 2/14 | 2/15 | 1/14 |
| HyponatremiaMETABOLISM AND NUTRITION DISORDERS | 2/14 | 1/15 | 0/14 |
| HyperglycemiaMETABOLISM AND NUTRITION DISORDERS | 0/14 | 2/15 | 1/14 |
| AnemiaBLOOD AND LYMPHATIC SYSTEM DISORDERS | 0/14 | 0/15 | 1/14 |
| HemolysisBLOOD AND LYMPHATIC SYSTEM DISORDERS | 1/14 | 0/15 | 0/14 |
| Adrenal insufficiencyENDOCRINE DISORDERS | 1/14 | 0/15 | 0/14 |
| Abdominal painGASTROINTESTINAL DISORDERS | 0/14 | 1/15 | 1/14 |
| DiarrheaGASTROINTESTINAL DISORDERS | 0/14 | 1/15 | 1/14 |
| NauseaGASTROINTESTINAL DISORDERS | 0/14 | 1/15 | 1/14 |
| Event | Relatlimab | Nivolumab | Relatlimab + Nivolumab |
|---|---|---|---|
| FatigueGENERAL DISORDERS | 11/14 | 9/15 | 11/14 |
| HyponatremiaMETABOLISM AND NUTRITION DISORDERS | 11/14 | 9/15 | 11/14 |
| AnemiaBLOOD AND LYMPHATIC SYSTEM DISORDERS | 9/14 | 8/15 | 9/14 |
| Blood lactate dehydrogenase increasedINVESTIGATIONS | 8/14 | 9/15 | 8/14 |
| NauseaGASTROINTESTINAL DISORDERS | 8/14 | 7/15 | 8/14 |
| Weight lossINVESTIGATIONS | 8/14 | 3/15 | 8/14 |
| HyperglycemiaMETABOLISM AND NUTRITION DISORDERS | 4/14 | 8/15 | 4/14 |
| Sinus bradycardiaCARDIAC DISORDERS | 6/14 | 4/15 | 6/14 |
| Aspartate aminotransferase increasedINVESTIGATIONS | 6/14 | 4/15 | 6/14 |
| Creatinine increasedINVESTIGATIONS | 6/14 | 2/15 | 6/14 |
| Age, Continuous(years) | Relatlimab | Nivolumab | Relatlimab + Nivolumab | Total |
|---|---|---|---|---|
| Median | 70.00 (53.00 to 76.00) | 69.00 (35.00 to 88.00) | 60.00 (38.00 to 87.00) | 67.00 (35.00 to 88.00) |
| Sex: Female, Male(Participants) | Relatlimab | Nivolumab | Relatlimab + Nivolumab | Total |
|---|---|---|---|---|
| Female | 4 | 7 | 4 | 15 |
| Male | 10 | 8 | 10 | 28 |
| Ethnicity (NIH/OMB)(Participants) | Relatlimab | Nivolumab | Relatlimab + Nivolumab | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 14 | 15 | 14 | 43 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Relatlimab | Nivolumab | Relatlimab + Nivolumab | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 14 | 15 | 14 | 43 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| BRAF.STATUS(Participants) | Relatlimab | Nivolumab | Relatlimab + Nivolumab | Total |
|---|---|---|---|---|
| Wild-Type | 4 | 9 | 7 | 20 |
| Mutated | 7 | 5 | 6 | 18 |
| Unknown | 3 | 1 | 1 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2019 to primary completion in Jul 2024, 63 months.
Results were first posted in Aug 2026, 2 years 1 month after primary completion.
Of 277 non-industry phase 2 interventional studies under Melanoma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's 63 months is close to that.
Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Relatlimab · Nivolumab
John Kirkwood